Search PubMed⌕ Search

Biomedical subjects

M J Wang

Publications and source records attributed to M J Wang.

83 records · Page 5Linked to original sources
PubMed1984

Clinical trial on furapyrimidone in filariasis.

A clinical trial was carried out with furapyrimidone in treating 51 patients with B. malayi, 159 with W. bancrofti and eight with D. perstans using different dosage schedules. Two hundred and fifty-seven cases of Malayan and bancroftian filariasis were treated with hetrazan for comparison. The results based on the microfilaricidal effects suggest that furapyrimidone possesses similar therapeutic effects of hetrazan on Malayan filariasis at eight-month follow-up, and higher incidences of microfilarial disappearance of W. bancrofti infection (81.3%) at six-month follow-up. The drug was also effective against D. perstans. The side effects consisted of fever and irritation of the digestive tract. Fever may be related to allergic reaction of foreign protein from the dead or dying parasites. The side reactions are similar to those of hetrazan and usually not serious. Comparing the efficacies and side effects of furapyrimidone with different dosage schedules the authors recommend regimens of 15 to 20 mg/kg/day for six days in treating Malayan filariasis and 20 mg/kg/day for seven days in treating bancroftian filariasis.

Adolescent↗
PubMedDate not supplied

Evaluating the effects of interface factors on the torque exertion capabilities of operating handwheels.

This study intends to assess factors affecting human torque exertion capabilities of operating valve handwheels (maximum volitional torque exertion of wrist radial/ulnar deviation, R/U MVTE). Forty student subjects (20 males and 20 females) participated in this study. In addition to gender and subject factors, gloves (one layer of cotton, two layers of cotton and rubber gloves), operating height (elbow, shoulder and overhead), handwheel size and shape were selected. Barehanded condition was also involved. The results indicate that all the main effects and the first order interactions were significant. The gloved R/U MVTEs were found to be greater than the barehanded R/U MVTE. For operating height, shoulder height gave the greatest R/U MVTE, followed by elbow and overhead heights. The handwheel diameters ranging from 75 to 95 mm for males and 65 to 80 mm for females were found to have the greater R/U shear force. The average R/U MVTE of operating valve handwheel for females was about 63% (3.8/6.05) of that of males.

Accidents, Occupational↗
PubMedDate not supplied

Purification and characterization of a Hodgkin's and B cell-associated glycoprotein.

A glycoprotein (BLA.36), expressed on the plasma membrane of Hodgkin's cells and also on normal and malignant B lymphocytes and histiocytes, was identified by reaction with a monoclonal antibody. BLA.36 was not detectable on other hematopoietic, carcinoma or melanoma cell lines. BLA.36 was purified to homogeneity by extracting proteins from a Hodgkin's cell line (HDLM-3), followed by immunoaffinity chromatography, utilizing immobilized anti-BLA.36 antibody, and gel filtration on Sephacryl S-100 in the presence of protein dissociating agents. The purified component yielded a single band on sodium dodecyl sulphate/polyacrylamide gel electrophoresis under both non-reducing and reducing conditions, and closely related three isotypes of similar molecular weight and with the apparent isoelectric points that ranged from 5.0 to 5.2 on two-dimensional gel electrophoresis. The purified BLA.36 reacted with the original specific antibody, on both one- or two-dimensional gel electrophoresis, suggesting that antigenic determinant was not adversely affected during purification procedure. Competitive immunoprecipitation analyses and the determination of N-terminus sequence of the first 13 amino acid residues suggest that BLA.36 is unrelated to other known Hodgkin's or hematopoietic cell antigens. Finally, significance of BLA.36 expression on the growth of BLA.36-positive cell lines was studied. Blocking of BLA.36 with anti-BLA.36 antibody led to the in vitro growth-inhibition of BLA.36-positive cell lines. The antibody pre-absorbed with the purified BLA.36 was unable to exert growth-inhibition, demonstrating the specificity of reaction. In addition, the treatment of the BLA.36-positive cell lines with differentiation-inducing agent, alpha-interferon (alpha-IFN), down-regulated BLA.36 expression and also showed in vitro growth-inhibition of BLA.36-positive cell lines. Taken together, these results suggest a growth-related function of BLA.36.

Amino Acid Sequence↗
PubMedDate not supplied

A sialoglycoprotein (LEA.135) associated with favourable prognosis of patients with lymph node-negative primary breast carcinoma.

A cell-surface sialoglycoprotein (LEA.135) was identified using a monoclonal antibody that was generated by immunization of Balb/c mice with extracts of normal breast tissue following prior immune-tolerization with mammary carcinoma cell lines. LEA.135 is distinct from other known epithelial cell-associated antigens, including the family of mucins or keratins and epidermal growth factor receptor. Using immunohistochemical staining methods, LEA.135 expression was detected predominantly on the apical plasma membrane of normal and neoplastic mammary and extramammary epithelial cells in freshly frozen or formalin-fixed paraffin-embedded tissue sections. A retrospective study of 111 cases of lymph node-negative patients (TanyN0M0) with primary infiltrating ductal breast carcinoma, with a median follow-up of 7.9 years, was conducted. A comparison of overall survival (O.S.) was made of patients whose tumor cells exhibited reactivity with anti-LEA.135 antibody (O.S. 92.9 +/- 3.3% at 8 years), compared with those whose specimens showed the absence of LEA.135 expression (O.S. 68.3 +/- 10.8% at 8 years). A statistically significant univariant association between LEA.135 expression and O.S. was observed (logrank p < 0.001). In addition, in a subgroup of patients with histologically moderately differentiated tumors (N = 71), LEA.135-positive cases showed an improved O.S. (90.8 +/- 4.6% at 8 years; p < 0.001) compared with those who were LEA.135-negative (O.S. 55.6 +/- 13.6% at 8 years). The association remained statistically significant in a multivariable analysis after adjusting for histological grade, tumor size and age (p < 0.02). Thus, in this series of patients with lymph node-negative primary breast carcinoma, LEA.135 expression was associated with a significant decrease in the rate of recurrence and with an increase in overall survival, independent of tumor size, histologic grade, and patient's age. In contrast to the majority of other prognostic markers which predicts a worse biology, LEA.135 is a unique class of antigen whose expression indicates a lower aggressiveness of the tumor cells.

Aged↗